Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2023, Vol. 28 ›› Issue (3): 241-248.doi: 10.12092/j.issn.1009-2501.2023.03.001

    Next Articles

Silybin ameliorates lipid metabolism disorders in mice with non-alco-holic steatohepatitis

CAI Zuhuan1, DENG Taomei1, WEI Naijie1, ZHU Dan2, QIAN Fei2, WANG Guangji1, ZHANG Jingwei1   

  1. 1Key Laboratory of Drug Metabolism & Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, Jiangsu, China; 2Jiangsu Provincial Hospital of Chinese Medicine, Affiliated to Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu, China 
  • Received:2022-04-12 Revised:2022-05-18 Online:2023-03-26 Published:2023-04-19

Abstract:

AIM: To investigate the regulatory ef-fects of silybin on hepatic lipid metabolism in mice with non-alcoholic steatohepatitis (NASH) induced by high -fat and high-cholesterol (HFHD) diet. METHODS: Mice were fed a HFHD diet to construct a NASH model, and serum levels of triacylglycerol (TAG), total cholesterol (T-CHO), low-density lipo-protein cholesterol (LDL-C) and high-density lipo-protein cholesterol (HDL-C) were measured using biochemical kits. H&E staining and oil red O stain-ing were used to detect histopathological changes in the liver. Lipidomics was used to detect the alter-ations of hepatic lipid metabolism in NASH mice. 
RESULTS: Silybin significantly inhibited the increase of body weight, liver weight and abdominal fat, de-creased serum T-CHO,TAG and LDL-C levels, im-proved hepatic lipid droplet accumulation and bal-looning degeneration, and back-regulated hepatic palmitoleic acid (C16:1) and polyunsaturated long-chain fatty acids (PUFAs) in NASH mice. CONCLU-SION: Silybin possibly reduced hepatic lipid accu-mulation and lipotoxicity by modulating abnormal hepatic lipid metabolism in mice induced by HFHC diet. 

Key words: silybin, non-alcoholic steatohepatitis, lipid metabolism 

CLC Number: